Why DexCom (DXCM) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Feb 20, 2026

The Big 3: VZ, DXCM, AMAT

Dan Deming sees the rotation trade continuing if markets can hold recent momentum this trading week. As for the Big 3, he sees a breakout candidate in Verizon (VZ), DexCom's (DXCM) potential to continue its recent upside momentum, and Applied Materials (AMAT) serving as a rising giant in the semiconductor trade.

DexCom Stock Falls Despite Q4 Earnings Beat, G7 Rollout Drives Growth

DXCM beats Q4 EPS estimates, posts 13% revenue growth and reiterates 2026 guidance as G7 15 Day rollout and margin gains drive momentum.

Zacks Investment Research • Feb 13, 2026

Dexcom beats quarterly estimates on strong demand for glucose monitors

Medical device maker Dexcom beat Wall Street estimates for fourth-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring systems.

Reuters • Feb 12, 2026

DexCom Reports Better-Than-Expected Q4 Results: Details

DexCom Inc. (NASDAQ:DXCM) shares were mostly flat in Thursday's extended trading after the company released its fourth-quarter earnings report.

Benzinga • Feb 12, 2026

DexCom, Inc. (DXCM) Q4 2025 Earnings Call Transcript

DexCom, Inc. (DXCM) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 13, 2026

Dexcom Reports Fourth Quarter and Fiscal Year 2025 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Fourth Quarter and Fiscal Year 2025 Financial Results.

Business Wire • Feb 12, 2026

DexCom (DXCM) Q4 Earnings and Revenues Top Estimates

DexCom (DXCM) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.45 per share a year ago.

Zacks Investment Research • Feb 12, 2026

Countdown to DexCom (DXCM) Q4 Earnings: Wall Street Forecasts for Key Metrics

Evaluate the expected performance of DexCom (DXCM) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks Investment Research • Feb 10, 2026

Will DXCM Deliver Q4 Earnings Beat on G7 Stabilization, Volume Growth?

DexCom heads into Q4 earnings with easing G7 issues, improving supply chains and rebounding U.S. new customer starts lifting revenue outlook.

Zacks Investment Research • Feb 10, 2026